sitem-insel AG

sitem-insel – the Swiss Institute for Translational and Entrepreneurial Medicine in Berne – was created to establish, operate and develop a National Center of Excellence that assists in the transition from research findings or prototypes to marketable products. It is organized as a non-profit public-private partnership.

Services

School

sitem-insel School offers university-level education taught by professors and lecturers from academia and industry.

sitem-insel Enabling Facilities provides infrastructure to foster cooperation between industrial partners, basic science, and clinic.

sitem-insel Promoting Services facilitates the path from invention to successful commercialization by shaping and optimizing regulatory processes.

What we do?

The mission of sitem-insel is to create and foster an enhanced environment for translational medicine in Switzerland. The strategy is based on three pillars:

sitem-insel School
university education for professionals in medical devices and life sciences industry

sitem-insel Enabling Facilities
specialized R&D workshops, laboratories, and equipment for industry, and academia

sitem-insel Promoting Services
promotes innovation and optimizes administrative and regulatory effort from bench to bedsides

What we want?

sitem-insel aims to establish and operate a national center of competence for translational medicine in Berne

What is translational medicine?

Translational medicine deals with the transition from new findings and products from industrial development and basic research to clinical application. This process-oriented discipline professionalizes the interaction between industry, universities, clinicians, regulatory bodies and investors.

How are we organized?

sitem-insel is an independent, non-profit public-private partnership with the legal form of a public limited company. Government funding of appr. CHF 50m has been approved for the start-up phase. Subsequently, sitem-insel will be financially independent.

Public

Private

Partnership

Events

March 6, 2019

1/19 MDR Support Panel: class IIb and III products

With the new MDR, the clinical evidence requirements for Class IIb and III products are increasing substantially. Find out how you can generate this evidence efficiently.

May 15, 2019

2/19 MDR Readiness Day: OBL, hazardous substances, combination products, and software

Event organized by: Swiss Medtech

During the MDR Readiness Day, manufacturers will have the opportunity to exchange ideas, answer open questions themselves and find out important discussion areas for them in the areas of development, technical documentation, registration, and market surveillance. Topics to be analyzed in depth by industry representatives will be dealt with in the subsequent MDR Support Panel.

June 17, 2019

2/19 MDR Support Panel: OBL, hazardous substances, combination products, and software

Own-brand-labeler (OBL), manufactures using hazardous substances, manufacturers of combination products or software developers will face many new challenges with the new MDR. Find out what you need to pay attention to in your products.

October 11, 2019

Open Strategy Paper Development Workshop

sitem-insel organizes together with its partners from University of Bern and from Universität Hamburg the first Open Strategy Paper Development Workshop on October 11, 2019. The keynote will be held by Richard Whittington from Saïd Business School, University of Oxford.

more events

News

January 2019

«Energy Harvesting» - An Alternative Energy Source for Cardiac Pacemakers

Conventional pacemakers have batteries which are responsible for the power supply of the device. These batteries have a finite energy storage capacity, which is why pacemaker generator changes are frequent due to battery exhaustion. Pacemakers without batteries are therefore highly desirable. Reoperations and resulting complications can thus be avoided. The following article by among others sitem-insel employee Dr. Adrian Zurbuchen gives an insight into the research and development activities in the field of battery-free pacemakers.

October 4, 2018

Newly elected CEO replaces former Managing Director

At the operational level, a handover will take place as planned on November 1, 2018. Dr. sc. nat. ETH Simon A. Rothen will take over the newly created CEO function from the former Managing Director Prof. em. Dr. med. Felix Frey.

October 4, 2018

Changes in management organization

As of January 1, 2019, Prof. Dr. med. dent. Daniel Buser will become Chairman of the Board of Directors of sitem-insel after Dr. h.c. Uwe E. Jocham held this position on an interim basis since autumn 2017.

Prof. Dr. Christian Leumann will newly join the strategic committee as a representative of the University of Bern. He fills the position of Dr. Daniel Odermatt, who passed away.